Lookup NU author(s): Professor Quentin Anstee
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2018 Macmillan Publishers Ltd., part of Springer Nature Nonalcoholic fatty liver disease (NAFLD) is a common, progressive liver disease that affects up to one-quarter of the adult population worldwide. The clinical and economic burden of NAFLD is mainly due to liver-related morbidity and mortality (nonalcoholic steatohepatitis, cirrhosis or hepatocellular carcinoma) and an increased risk of developing fatal and nonfatal cardiovascular disease, chronic kidney disease and certain types of extrahepatic cancers (for example, colorectal cancer and breast cancer). Additionally, there is now accumulating evidence that NAFLD adversely affects not only the coronary arteries (promoting accelerated coronary atherosclerosis) but also all other anatomical structures of the heart, conferring an increased risk of cardiomyopathy (mainly left ventricular diastolic dysfunction and hypertrophy, leading to the development of congestive heart failure), cardiac valvular calcification (mainly aortic-valve sclerosis), cardiac arrhythmias (mainly atrial fibrillation) and some cardiac conduction defects. This Review focuses on the association between NAFLD and non-ischaemia-related cardiac disease, discusses the putative pathophysiological mechanisms and briefly summarizes current treatment options for NAFLD that might also beneficially affect cardiac disease.
Author(s): Anstee QM, Mantovani A, Tilg H, Targher G
Publication type: Article
Publication status: Published
Journal: Nature Reviews Gastroenterology and Hepatology
Online publication date: 30/04/2018
Acceptance date: 02/04/2018
ISSN (print): 1759-5045
ISSN (electronic): 1759-5053
Publisher: Nature Publishing Group
Altmetrics provided by Altmetric